BWAY
BrainsWay Ltd.
$15.89
+$0.79(+5.23%)
46
Overall
25
Value
50
Tech
65
Quality
Market Cap
$596.09M
Volume
161.79K
52W Range
$5.01 - $17.35
Target Price
$16.00
Company Overview
| Mkt Cap | $596.09M | Price | $15.89 |
| Volume | 161.79K | Change | +5.23% |
| P/E Ratio | 78.7 | Open | $15.80 |
| Revenue | $52.2M | Prev Close | $15.10 |
| Net Income | $7.6M | 52W Range | $5.01 - $17.35 |
| Div Yield | N/A | Target | $16.00 |
| Overall | 46 | Value | 25 |
| Quality | 65 | Technical | 50 |
No chart data available
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
BrainsWay Takes Minority Stake in Hopemark Health to Expand Deep TMS Footprint
TipRanks Auto-Generated Newsdesk•9 days ago
BrainsWay Highlights Q1 2026 Surge in Revenue and Profitability as Deep TMS ARR Model Scales
TipRanks Auto-Generated Newsdesk•13 days ago
BrainsWay Highlights Q1 2026 Surge in Revenue and Profitability as Deep TMS ARR Model Scales
TipRanks Auto-Generated Newsdesk•13 days ago
BrainsWay Posts Strong Q1 2026 Growth and Reaffirms Outlook on Deep TMS Momentum
TipRanks Auto-Generated Newsdesk•14 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BWAY | $15.89 | +5.2% | 161.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |